Margins in breast-conserving therapy: Have we lost sight of the big picture?

Expert Review of Anticancer Therapy

Volumn 8, Issue 8, 2008, Pages 1193-1196

  Morrow, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLACEBO; TRASTUZUMAB;

ADJUVANT THERAPY; ANATOMICAL VARIATION; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DAILY LIFE ACTIVITY; EDITORIAL; EVIDENCE BASED PRACTICE; HEALTH SURVEY; HUMAN; INTERMETHOD COMPARISON; MASTECTOMY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; REOPERATION; SURGICAL ANATOMY; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREATMENT INDICATION; TUMOR CELL; BREAST TUMOR; FEMALE; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; SENTINEL LYMPH NODE BIOPSY;

EID: 54549086523     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.8.1193     Document Type: Editorial

References (24)

1. Morrow M, Hamilton AS, Katz SJ. Why do women get mastectomy? Results from a population based study J. Clin. Oncol. 25(18S), 28S (2007) (Abstract 605).
2. Taghian A, Mohiuddin M, Jagsi R, Goldberg S, Ceilley E, Powell S. Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey. Ann. Surg. 241(4), 629-639 (2005).
3. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med. 347(16), 1233-1241 (2002).
4. Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 347(16), 1227-1232 (2002).
5. Sarrazin D, Le MG, Arriagada R et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother. Oncol. 14(3), 177-184 (1989).
6. Poggi MM, Danforth DN, Sciuto LC et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98(4), 697-702 (2003).
7. van Dongen JA, Voogd AC, Fentiman IS et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J. Natl Cancer Inst. 92(14), 1143-1150 (2000).
8. Luini A, Rososchansky J, Gatti G et al. The surgical margin status after breast-conserving surgery: discussion of an open issue. Breast Cancer Res. Treat. (2008) (Epub ahead of print).
9. Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am. J. Surg. 184(5), 383-393 (2002).
10. Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 56(5), 979-990 (1985).
11. Rosen PP, Menendez-Botet CJ, Nisselbaum JS et al. Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res. 35(11 Pt 1), 3187-3194 (1975).
12. Carter D. Margins of "lumpectomy" for breast cancer. Hum. Pathol. 17(4), 330-332 (1986).
13. Schnitt SJ, Connolly JL. Processing and evaluation of breast excision specimens. A clinically oriented approach. Am. J. Clin. Pathol. 98(1), 125-137 (1992).
14. Graham RA, Homer MJ, Katz J, Rothschild J, Safaii H, Supran S. The pancake phenomenon contributes to the inaccuracy of margin assessment in patients with breast cancer. Am. J. Surg. 184(2), 89-93 (2002).
15. Holland R, Verbeek AL. Prognostic assessment in node-negative breast cancer patients. J. Clin. Oncol. 8(9), 1451-1453 (1990).
16. Neuschatz, AC, DiPetrillo, T, Steinhoff M et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer 94(7), 1917-1924 (2002).
17. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl Cancer Inst. 88(21), 1529-1542 (1996).
18. Fisher B, Dignam J, Mamounas EP et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings hom NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J. Clin. Oncol. 14(7), 1982-1992 (1996).
19. Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 26(14), 2373-2378 (2008).
20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (16), 1659-1672 (2005).
21. Romond EH, Perez EA. Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
22. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503), 2087-2106 (2005).
23. Wapnir I, Anderson S, Mamounas E, Geyer C. Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23. J. Clin. Oncol. 23(16S), 8s (2005) (Abstract 517).
24. Wapnir IL, Anderson SJ, Mamounas EP et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J. Clin. Oncol. 24(13), 2028-2037 (2006).